You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

bispecific antibody-armed activated T cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Cancer, Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma Trial in New York, Charlottesville

Active, not recruiting
  • Pancreatic Cancer
  • +3 more
  • anti-EGFR-bispecific antibody armed activated T-cells
  • New York, New York
  • +1 more
Oct 7, 2021

Multiple Myeloma Trial in Charlottesville (SLAMF7 BATs)

Not yet recruiting
  • Multiple Myeloma
  • SLAMF7 BATs
  • Charlottesville, Virginia
    University of Virginia
May 17, 2022

Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma Trial in Charlottesville (EGFR BATs after

Recruiting
  • Locally Advanced Pancreatic Adenocarcinoma
  • Metastatic Pancreatic Adenocarcinoma
  • EGFR BATs after standard of care chemo
  • Charlottesville, Virginia
    University of Virginia
Mar 30, 2022

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone Trial in

Recruiting
  • Castration Levels of Testosterone
  • +4 more
  • HER2Bi-Armed Activated T Cells
  • +2 more
  • Detroit, Michigan
    Wayne State University/Karmanos Cancer Institute
Feb 26, 2021

Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer Trial in Detroit (biological,

Completed
  • Metastatic Pancreatic Adenocarcinoma
  • +3 more
  • Aldesleukin
  • +9 more
  • Detroit, Michigan
    Wayne State University/Karmanos Cancer Institute
Mar 30, 2022

Breast Cancer Trial in Detroit (biological, drug, other)

Terminated
Has Results
  • Breast Cancer
  • HER2Bi-armed activated T cells
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Nov 29, 2022

Breast Cancer Female, Leptomeningeal Metastases Trial in Charlottesville (HER2 BATs)

Terminated
  • Breast Cancer Female
  • Leptomeningeal Metastases
  • HER2 BATs
  • Charlottesville, Virginia
    University of Virginia
Dec 15, 2022

Metastatic Breast Cancer Trial in Charlottesville (HER2 BATs with Pembrolizumab)

Recruiting
  • Metastatic Breast Cancer
  • HER2 BATs with Pembrolizumab
  • Charlottesville, Virginia
    Ashley Donihee
Jan 18, 2023

Colorectal Cancer, Cancer of Pancreas, Pancreatic Tumor Trial in Detroit (FOLFOX6, EGFRBi armed ATC Infusions)

Completed
  • Colorectal Cancer
  • +7 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
Mar 30, 2022

Advanced Liver Cancer Trial in Beijing (Activated CIK, CIK)

Recruiting
  • Advanced Liver Cancer
  • Activated CIK
  • CIK
  • Beijing, Beijing, China
    302 Military Hospital of China
Jan 27, 2021

Advanced Breast Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer,

Withdrawn
  • Advanced Breast Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer
  • cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Colorectal Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer,

Withdrawn
  • Advanced Colorectal Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer
  • Cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Pancreatic Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer,

Withdrawn
  • Advanced Pancreatic Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer
  • cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Lung Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer, Cryotherapy)

Withdrawn
  • Advanced Lung Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer
  • Cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Gastric Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer,

Withdrawn
  • Advanced Gastric Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer
  • Cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Kidney Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer,

Withdrawn
  • Advanced Kidney Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer
  • cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Liver Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer, cryotherapy)

Withdrawn
  • Advanced Liver Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer
  • cryotherapy
  • Guangzhou, Guangdong, China
  • +1 more
Oct 13, 2020

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +9 more
  • Anti-CD30/CD16A Monoclonal Antibody AFM13
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Acute Myeloid Leukemia, Relapsed AML, Refractory AML Trial in Germany (GEM333)

Terminated
  • Acute Myeloid Leukemia
  • +2 more
  • Mannheim, Baden-Württemberg, Germany
  • +6 more
Sep 28, 2022

Breast Cancer, Uterine Cancer, Ovarian Cancer Trial in Denmark, France, Spain (GEN1047 is a bispecific antibody that induces

Recruiting
  • Breast Cancer
  • +3 more
  • GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.
  • Copenhagen, Denmark
  • +5 more
Jul 25, 2022

Disseminated Neuroblastoma, Recurrent Neuroblastoma Trial in Detroit, New York, Charlottesville (IL-2, GD2Bi-aATC, GM-CSF)

Unknown status
  • Disseminated Neuroblastoma
  • Recurrent Neuroblastoma
  • IL-2
  • +3 more
  • Detroit, Michigan
  • +2 more
Jan 25, 2019

Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (AZD5863)

Recruiting
  • Gastric Cancer
  • +3 more
  • Jacksonville, Florida
  • +16 more
Aug 17, 2023

Colorectal Cancer Trial in Tianjin (Bevacizumab Injection [Avastin], Oxaliplatin, Capecitabine)

Unknown status
  • Colorectal Cancer
  • Bevacizumab Injection [Avastin]
  • +3 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jul 5, 2020